Skip to main content
. Author manuscript; available in PMC: 2017 Feb 15.
Published in final edited form as: J Immunol. 2016 Jan 15;196(4):1443–1448. doi: 10.4049/jimmunol.1501634

Figure 2. Anti-CD99 ameliorates RR-EAE and reduces histopathological burden.

Figure 2

(A) Comparison of mean clinical score between mice treated (arrows) with anti-CD99 (open circles) or control IgG (closed circles) at onset of clinical symptoms and every other day thereafter. (B) Whole mount immunostaining of spinal cord parenchymal postcapillary venules (PECAM-1; red) and CD3+ T-cell (green) infiltrates from anti-CD99 (lower panels) or control-IgG (upper panels) treated mice at peak of disease. Data shown are representative of 3 independent experiments (A,B) with a minimum of 5 mice per group and from >20 immunostainings performed on post-mortem material from 3 animals/group (B). Scale bar = 26μm. Error bars indicate SEM. **p< 0.001 (Mann-Whitney U test).